All In Biotech

Drug Trial Radar · NCT04185441

Efficacy and Safety of Tanzânia Association in the Treatment of Erectile Dysfunction Associated With Benign Prostatic Hyperplasia

National, Multicenter, Randomized, Double-blind, Double-dummy, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Tanzânia Association in the Treatment of Erectile Dysfunction Associated With Benign Prostatic Hyperplasia

Last checked: Nov 20, 2026Latest source record: Dec 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 295 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

295

Actual

Start

Mar 14, 2021

Primary completion

Oct 10, 2023

Study completion Jul 5, 2024

Sponsor

Lead sponsor
EMSIndustry
Sponsor type
Industry
First posted
Dec 4, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of Tanzânia association in adults with erectile dysfunction associated with Benign Prostatic Hyperplasia.

Conditions

  • Erectile Dysfunction
  • Benign Prostatic Hyperplasia

Interventions

  • Tanzânia associationDrug

    Tanzânia association capsule

  • Omnic OcasDrug

    Tamsulosin 0,4 mg

  • Omnic Ocas placeboOther

    Tamsulosin placebo

  • Tanzânia association placeboOther

    EMS association placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in erectile function questionnaire.Time frame: 8 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Allergisa

    Campinas, São Paulo, Brazil

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.